Get the Stockscreener App
1.20
0.00%
0.00
Skye Bioscience Inc stock is traded at $1.20, with a volume of 199.38K.
It is up +0.00% in the last 24 hours and down -20.53% over the past month.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
See More
Previous Close:
$1.20
Open:
$1.22
24h Volume:
199.38K
Relative Volume:
0.25
Market Cap:
$38.47M
Revenue:
-
Net Income/Loss:
$-42.37M
P/E Ratio:
-1.123
EPS:
-1.0686
Net Cash Flow:
$-34.94M
1W Performance:
-8.40%
1M Performance:
-20.53%
6M Performance:
-44.19%
1Y Performance:
-66.20%
1-Day Range:
$1.18
$1.2898
1-Week Range:
$1.10
$1.30
52-Week Range:
$1.10
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
Name
Skye Bioscience Inc
Sector
Industry
Phone
(858) 410-0266
Address
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
3.50 | 4.01B | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2215 | 480.44M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.09 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.67 | 220.48M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.90 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-06-25 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-15-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Sep-30-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-09-24 | Initiated | Craig Hallum | Buy |
| May-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-24 | Initiated | Oppenheimer | Outperform |
View All
Skye Bioscience Inc Stock (SKYE) Latest News
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE - GlobeNewswire Inc.
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Skye Bioscience, Inc. (SKYE) Investors of January 16, 2026 Deadline - ACCESS Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - Newsfile
SKYE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Skye Bioscience, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Will Skye Bioscience Inc. (09R) stock profit from fiscal stimulusQuarterly Portfolio Summary & High Accuracy Buy Signal Tips - Newser
Skye Bioscience, Inc. Class Action: Levi & Korsinsky - GlobeNewswire
SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors - GlobeNewswire
Shareholders of Skye Bioscience, Inc. Should Contact The Gross Law Firm Before January 16, 2026 to Discuss Your RightsSKYE - WV News
Will Skye Bioscience Inc. (09R) stock gain from lower interest ratesJuly 2025 Technicals & Long-Term Safe Investment Ideas - Newser
Bragar Eagel & Squire, P.C. Urges DeFi, Skye Bioscience, - GlobeNewswire
SueWallSt With Us: Levi & Korsinsky Notifies Shareholders of Class Action Against Skye Bioscience, Inc - ACCESS Newswire
Investors in Skye Bioscience, Inc. Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your RightsSKYE - WV News
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - GlobeNewswire
You might want to take a look at Skye Bioscience Inc (SKYE) now - Setenews
SKYE Class Action Reminder: Skye Bioscience, Inc. Stockholders Should Contact Robbins LLP for Information About the Securities Class Action Lawsuit - lelezard.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - Stockhouse
SKYE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Skye Bioscience, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Skye Bioscience, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm for More InformationSKYE - Lelezard
Is Skye Bioscience Inc. (09R) stock resilient in recession scenarios2025 Short Interest & Safe Swing Trade Setup Alerts - Newser
Is Skye Bioscience Inc. (09R) stock prepared for digital transitionGap Down & Long-Term Capital Growth Strategies - Newser
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit - Your Wyoming Link
Skye Bioscience, Inc. (NASDAQ: SKYE) Securities Class - GlobeNewswire
January 16, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SKYE - GlobeNewswire
What analysts say about Skye Bioscience Inc 09R stockHigh Dividend Yield Stocks & Low Risk Trading Portfolio - earlytimes.in
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Se - GuruFocus
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. - GlobeNewswire
SKYE STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Skye Bioscience, Inc. Investors to Secure Counsel ... - Bakersfield.com
Will Skye Bioscience Inc. stock keep outperforming rivalsTrade Risk Assessment & Reliable Entry Point Alerts - BỘ NỘI VỤ
Skye Bioscience, Inc. Class Action: The Gross Law Firm Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026SKYE - Eastern Progress
Levi & Korsinsky Invites Investors to SueWallSt After Skye Bioscience, Inc. Stock Collapse - ACCESS Newswire
Levi & Korsinsky Reminds Skye Bioscience, Inc. Investors of - GlobeNewswire
SKYE Stockholders with Large Losses Should Contact Robbins - GlobeNewswire
Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your RightsSKYE - NewMediaWire
Skye Bioscience, Inc. Class Action: Levi & Korsinsky Reminds Sky - GuruFocus
Skye Bioscience, Inc. Class Action: Levi & Korsinsky Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026SKYE - Morningstar
Bragar Eagel & Squire, P.C. Reminds Stockholders Spirit, - GlobeNewswire
Shareholders that lost money on Skye Bioscience, Inc. - GlobeNewswire
Lost Money on Skye Bioscience, Inc. (SKYE)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - NewMediaWire
Skye Bioscience, Inc. Class Action: The Gross Law Firm Reminds S - GuruFocus
Skye Bioscience to Participate in Upcoming Investment Conferences - Barchart.com
Skye Bioscience : Corporate Presentation View Presentation ( 251114 Skye Investor Deck Final ) - MarketScreener
Skye Bioscience (NASDAQ: SKYE) to join Citi, Evercore and Piper Sandler healthcare investment conferences - Stock Titan
Skye Bioscience Inc Stock (SKYE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):